Neil Crittenden, MD
Gastroenterology · Oklahoma City, OKNPI 1598907115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 32.5% of the total. 2025 is the largest year on record at $2,238, more than ten times the $70 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in OK, where the typical reported total is $4,832.
Across 140 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$894
- Johnson & Johnson$198
- Medtronic$197
- Lilly USA, LLC$175
- Sanofi$170
- Gilead$167
- plus $947 from 18 others
Across 15 payments — averaging $9344.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$98K
- AbbVie$42K
- Eli Lilly$16
What the payments were for
- Food & beverage$2,748100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $894 |
| Johnson & Johnson | 17 | $198 |
| Medtronic | 4 | $197 |
| Lilly USA, LLC | 7 | $175 |
| Sanofi | 3 | $170 |
| Gilead | 8 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $149 |
| Pfizer | 8 | $124 |
| Madrigal Pharmaceuticals | 4 | $103 |
| QOL Medical, LLC | 4 | $101 |
| Celltrion USA Inc. | 4 | $84 |
| Aimmune Therapeutics, Inc. | 4 | $83 |
| Ipsen Biopharmaceuticals, Inc | 4 | $68 |
| Phathom Pharmaceuticals, Inc. | 5 | $55 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Amgen | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Micro-tech Endoscopy USA, Inc. | 1 | $9 |
| Romark Laboratories, LC | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,748 in reported general payments places this provider in the 45th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 32 | $54,140 |
| ZenpepLipase/Protease/Amylase | 11 | $35,989 |
| LinzessLinaclotide | 25 | $21,111 |
| Mesalamine | 40 | $13,930 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 136 | $8,376 |
| Pantoprazole Sodium | 255 | $4,640 |
| Omeprazole | 142 | $3,092 |
| Budesonide DrBudesonide | 24 | $2,498 |
| Ursodiol | 16 | $1,952 |
| Mesalamine ErMesalamine | 14 | $1,591 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 108 | $1,573 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 98 | $1,481 |
| Sucralfate | 24 | $1,280 |
| Famotidine | 52 | $702 |
| Tenofovir Disoproxil Fumarate | 11 | $691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $894 | $75,25157 claims |
| Aimmune Therapeutics, Inc.Zenpep | $83 | $35,98911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Oklahoma City
- George SalemOklahoma City$1.2M
- Tauseef AliOklahoma City$536K
- Pooja SinghalOklahoma City$140K
- Hussein BitarOklahoma City$120K
- Trushar PatelOklahoma City$49K
- Matthew McBrideOklahoma City$33K
- Sanjay SikkaOklahoma City$31K
- Tony TranOklahoma City$11K
- Ahmad Al-TaeeOklahoma City$11K
- Sumit WaliaOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.